menu
    • menu
    [{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AstroRx","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Not Applicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio \/ Not Applicable"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CDNF","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral infusion","sponsorNew":"Herantis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Regenacy Pharmaceuticals","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Ricolinostat","moa":"HDAC6","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Regenacy Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Regenacy Pharmaceuticals \/ Cobro Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Regenacy Pharmaceuticals \/ Cobro Ventures"},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Alpha-1062","moa":"AchE","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"AXO-Lenti-PD","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Sio Gene Therapies"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Human astrocytes","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Not Applicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PBFT02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"BOL Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"BOL-DP-o-04","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ BOL Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Kindeva Drug Delivery \/ BOL Pharma"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Human astrocytes","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Not Applicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"PBFT02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Nanoform","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Cerebral Dopamine Neurotrophic Factor","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral infusion","sponsorNew":"Herantis Pharma \/ Nanoform","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Nanoform"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human pluripotent stem cells","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"GAL-201","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galimedix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SPG302","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Spartan Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Stereopure antisense oligonucleotide","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Alcami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Alcami","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Alcami"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AXO-Lenti-PD","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Sio Gene Therapies"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Hadassah Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"NeuroGenesis \/ Hadassah Medical Center"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DNL593","moa":"Progranulin protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Orcosa","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Orcosa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Orcosa \/ NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"Orcosa \/ NYU Langone Health"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"BitNile Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ALZN002","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ BitNile Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ BitNile Holdings"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TAK-594","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Denali Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Biorasi"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Adult Mesenchymal Bone Marrow Stem Cell","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica Cell Technologies \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"SON-080","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NE3107","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ALZN002","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp. IV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp. IV","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp. IV"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"MJFF","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"VENT-02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ MJFF","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ MJFF"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Suramin","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PaxMedica \/ Not Applicable"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ANPD001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Aspen Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VENT-02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"IMCY-0141","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imcyse \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imcyse \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"JM17","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PaxMedica","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"PaxMedica \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"JM17","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"Mitochon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MP101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Mitochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Mitochon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mitochon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ETX101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"NRTX-1001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Neurona Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ETX101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"PBFT02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"The Ohio State University Wexner Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AAV-PGRN","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AviadoBio \/ The Ohio State University Wexner Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ The Ohio State University Wexner Medical Center"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"JNJ-2056","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Troculeucel","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kine Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"KINE-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kine Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Kine Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kine Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PBFT02","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"JNJ-2056","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0.51000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NRTX-1001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ CIRM"},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AMT-162","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":2.23,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":2.23,"dosageForm":"","sponsorNew":"AviadoBio \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Astellas Pharma"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"BXQ-350","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bexion Pharmaceuticals \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AAV-GAD","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"MeiraGTx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Trontinemab","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AMT-260","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Not Applicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"BXQ-350","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"S.Biomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TED-A9","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"S.Biomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"S.Biomedics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"S.Biomedics \/ Not Applicable"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Mytos","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"ANPD001","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Aspen Neuroscience \/ Mytos","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Mytos"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBFT02","moa":"GRN","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-162","moa":"SOD1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ETX101","moa":"SCN1A gene expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201-DDT","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"EG 427","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intradetrusor Injection","sponsorNew":"EG 427 \/ Andera Partners","highestDevelopmentStatusID":"7","companyTruncated":"EG 427 \/ Andera Partners"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrahippocampal Infusion","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Termination","leadProduct":"WVE-003","moa":"SNP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-120102","moa":"SNP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Columbus Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Columbus Venture Partners"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ Inapplicable"}]

    Find Neurology Drugs in Phase I/II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ventus Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Ventus Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VENT-02

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ventus Doses First Patient in Phase 2a Trial of VENT-02 in Parkinson’s

                            Details : VENT-02 is a novel, oral, brain-penetrant inhibitor of NLRP3, being investigated in patients with mild to moderate Parkinson’s disease.

                            Product Name : VENT-02

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : VENT-02

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica’s PP353 Phase 1b Shows Promise for Chronic Low Back Pain

                            Details : PP353 is an antibiotic formulation designed for intradiscal injection under image guidance. It is being evaluated for the treatment of chronic lower back pain.

                            Product Name : PP353

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EG 427

                            France arrow
                            DCAT Week
                            Not Confirmed

                            EG 427

                            France arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG110A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EG 427 Doses First Patient with EG110A for Neurogenic Bladder

                            Details : EG110A is a gene therapy for the treatment which works by silencing the type-C neurons, being developed for Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.

                            Product Name : EG110A

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 27, 2025

                            Lead Product(s) : EG110A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alzamend Neuro

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Alzamend Neuro

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alzamend Sets Phase II Start Date for AL001 at Massachusetts General Hospital

                            Details : AL001 (lithium salicylate proline) is an oral small molecule BDNF inhibitor. It is being developed for the treatment of petients with alzheimer’s disease.

                            Product Name : AL001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Lithium Salicylate Proline

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GRIN Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            GRIN Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil

                            Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.

                            Product Name : RGH-896

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EG 427

                            France arrow
                            DCAT Week
                            Not Confirmed

                            EG 427

                            France arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG110A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Andera Partners

                            Deal Size : $28.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            EG 427 Secures €27M in Series B for Clinical Study, Platform Development

                            Details : The company intends to finance phase 1b/2a study of EG110A, a genetic medicine utilizing a non-replicating HSV-1 vector, through safety and early efficacy results.

                            Product Name : EG110A

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : EG110A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Andera Partners

                            Deal Size : $28.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neurona Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Neurona Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRTX-1001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

                            Details : NRTX-1001, comprising GABAergic interneurons is a GABA inhibitor. It is being evaluated for the treatment of drug-resistant mesial temporal lobe epilepsy.

                            Product Name : NRTX-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : NRTX-1001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Creative Medical Technology

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Creative Medical Technology

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Creative Medical Reports Opioid Reduction in StemSpine® Mid-Term Study

                            Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.

                            Product Name : AlloStem

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : CELZ-201-DDT

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Encoded Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Encoded Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Encoded Updates on ETX101 for Dravet, Highlights 2024 Wins, Shares 2025 Plan

                            Details : ETX101 is an AAV9-mediated gene regulation therapy designed to upregulate expression of the SCN1A gene in GABAergic inhibitory interneurons. It is being evaluated for the treatment of Dravet syndrome.

                            Product Name : ETX101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : ETX101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NKGen Biotech

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NKGen Gets FDA Fast Track for Troculeucel in Moderate Alzheimer’s Disease

                            Details : SNK01(troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for moderate Alzheimer’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth